Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of oral infigratinib in Japanese patients with FGFR-altered advanced solid tumors
jRCTs041180017Completed
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of infigratinib in Nonhematologic neoplasms. Primary endpoint: Long-term safety. Started Feb 2019; status: completed.
02
Drugs
infigratinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCTs041180017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180017.